A study of the investigational drug MCLA-128 which is an antibody that is specific to both HER2 and HER3 receptors that are associated with solid tumors Part 1: - Determination of MTD/MRD and tolerability - Evaluation of adverse events (AEs) and dose limiting toxicities (DLT) Part 2: Primary Safety End Point: - To characterize the safety and t...

• Country None
• organs None
• Specialty None